NCT03574779 2025-07-15
OPAL
Tesaro, Inc.
Phase 2 Completed
Clinical Trials
6 trialsNCT06023862 2025-06-15
DOVE
Yonsei University
Phase 2 Recruiting
NCT05126342 2025-04-06
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
AGO Research GmbH
Phase 2 Withdrawn
NCT05065021 2024-01-17
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
Phase 2 Unknown
NCT05751629 2023-04-21
COHORT-A
Tesaro, Inc.
Phase 2 Completed
NCT03955471 2022-09-10
MOONSTONE
Tesaro, Inc.
Phase 2 Terminated